About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT02579551

Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery

This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face. A margin is the area of normal tis...

Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

PRIMARY OBJECTIVES: I. To determine the success rate of narrow margin excisions of low-risk facial basal cell carcinoma (BCC). SECONDARY OBJECTIVES: I. To determine the narrowest excision margin for low-risk facial BCC that gives an acceptable (95%) cure rate over a 3 year follow-up period.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Location
•1. Area M (cheeks, forehead, scalp \& neck) tumor size \< 10 mm
•2. Area H (central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular \& postauricular, temple \& ear) tumor size \< 6 mm
•2. Well-defined borders
•3. Primary BCC
•4. Patient is not immunosuppressed
•5. There has not been prior radiotherapy to the site
•6. Nodular subtype
•7. No perineural involvement-(no neurological deficits grossly) -

Exclusion Criteria

•1. Location
•1. Area M tumor size \> or = to 10 mm
•2. Area H tumor size \> or = to 6 mm
•2. Poorly defined borders
•3. Recurrent BCC
•4. Patient is immunosuppressed
•5. There has been prior radiotherapy to the site -

Related studies

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

NCT06539468 · Skin Basal Cell Carcinoma

RECRUITINGEARLY Phase 1

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

NCT07144384 · Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, and more

COMPLETEDPhase 2

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

NCT03180528 · Skin Basal Cell Carcinoma

WITHDRAWNEARLY Phase 1

Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer

NCT02699723 · Skin Basal Cell Carcinoma

TERMINATEDPhase 2

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

NCT01033019 · Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 29, 2025Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment179

Start dateDec 2011

Last updatedApr 29, 2025

Condition

Skin Basal Cell Carcinoma

Locations shown

Thomas Jefferson Univeristy

Philadelphia, Pennsylvania

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions